Seoul Economic Daily EnglishCodex · 实盘不做把握 5/10不做原因:证据不足
北京时间·🕒 发布 08:22:41(首尔 09:22)·⟳ 抓取 08:39:36 +16m55s·⚡ 决策 08-28 14:45:16 +6h05m·60.5 天前
CS5001一线DLBCL 1b期联合疗法31例完全缓解率达100%，但仍属早期临床且交易执行证据不足
事件本身是明确临床正面更新，但当前环境没有可用stock_tools完成交易前强制的经验、去重、行情、市值、案例库和event_study；在缺少真实入场价与可回测报价的情况下不能给ENTER。
📄 原文Seoul Economic Daily English↗ 原文
ABL Bio Partner Reports 100% Complete Response in Lymphoma Trial
CStone Pharmaceuticals, a global partner of ABL Bio (298380), confirmed a 100% complete response rate in a Phase 1b tri…
不做 ABL Bio（298380.KQ）
事件利多但韩国市场已收盘，且本轮未能取得stock_tools真实报价、市值、案例库与event_study，不能给可执行入场价。
不做 LigaChem Biosciences（141080.KQ）
平台验证逻辑正面，但仍是1b期小样本且临床暂停优化剂量；缺少强制行情与先例实测，不做。
不做 CStone Pharmaceuticals（02616.HK）
直接开发方受益但8月股价已有明显上涨，本轮缺少实时港股行情、市值和event_study，无法确认剩余edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
CS5001在31例一线DLBCL联合R-CHOP队列中披露ORR和CR均100%，对ABL Bio、LigaChem与CStone均属正面临床读出；但仍是1b期小样本，且公司同时临时暂停试验做剂量与给药间隔优化。新闻在韩国当地上午已由Seoul Economic Daily、Edaily、BioSpectator、LigaChem IR等多源扩散，韩国市场当前已收盘。本轮无法取得stock_tools真实报价、市值、案例库和event_study，因此不满足ENTER的执行与证据契约。
消息传播链
- 可见文件转述CStone中期报告披露CS5001一线DLBCL 31例ORR 100%、CR 100%，并称暂停试验以优化剂量和给药计划。
- 韩国药业媒体较早报道LigaChem称CStone通过半年度报告披露数据。
- 韩国综合媒体扩散LigaChem与ABL Bio共同开发CS5001完全缓解率100%的消息。
- 本次信号来源报道ABL Bio称CStone披露Phase 1b数据，并给出31例、40-90μg/kg和2020年约4000亿韩元授权交易等核心事实。
- LigaChem官网IR发布同一临床数据，确认CS5001/LCB71在一线DLBCL联合治疗中ORR和CR均为100%。
关键理由
- 31例一线DLBCL患者ORR和CR均100%，且最低40μg/kg剂量也见完全缓解，提升CS5001后续开发可信度。
- CS5001由ABL Bio与LigaChem共同开发并授权CStone，正面临床数据理论上改善授权资产的里程碑和估值预期。
- 量级上原授权交易约4000亿韩元，但本次未披露新增付款或商业化时间表，短线只能按临床资产估值重估而非确定收入增量处理。
主要风险
- 该结果仍为1b期、31例小样本，且CStone临时暂停试验优化剂量和给药间隔，后续安全性、持久缓解和注册路径仍未确认。
- 缺少本轮真实行情和市值，不能判断事件是否已在8月早前CStone及韩国ADC标的上涨中部分price-in。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-28 · 影响 weakens
多家报道均提到CStone将临时暂停当前试验以评估长期获益风险并优化剂量与给药间隔，这不是直接失败但削弱立即重仓追多的确定性。
检索:CS5001 trial temporarily paused dose schedule optimization safety risk 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-28 · 影响 weakens
可见资料确认样本量仅31例、仍为Phase 1b，尚无注册性试验、持续缓解、商业化权益分配和新增付款量化。
检索:CStone CS5001 interim report 31 patients ORR CR 100% first line DLBCL 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-27 · 影响 weakens
CStone 8月已从约4.32港元升至6.37港元，存在本次具体数据披露前的拥挤或预期交易风险，但不能单独证明完全price-in。
检索:2616 HK CStone stock August 2026 price run up CS5001 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足和行情缺口共同把结论压到不下单；不否定事件正面性，但否定本轮可执行ENTER。
方向:公开资料能支持临床资产估值方向为正，但没有完成stock_tools event_study，不能把先例转化为胜率或幅度。
涨幅量级:缺少高相似、同市场、同相位且已实测的先例，无法校准目标涨幅和止损。
形态:CStone 8月此前已有多日上涨，提示ADC/资产进展可能已部分交易，但未能区分行业beta、旧催化与本次新增事实。
历史先例(按相似度)
- 相似度 6/10 141080.KQ 2024-05-24 LigaChem 2024年披露CStone在ASCO摘要中公布CS5001 Phase 1a/1b初始临床数据。 原文 ↗
事件后 +1日 +1.6% · +2日 -4.7% · +3日 -4.8% · +4日 -7.1% · +5日 -3.5%
⚠来源层级不符(声明issuer/实为media)·盘中首发但只有日线，混入首发前走势 — 该行涨幅别用来定止盈止损
相似度依据:同一资产CS5001/LCB71的早期临床数据披露，但适应症/阶段和样本成熟度低于本次。
经验:同一ADC资产的早期数据披露可验证技术平台叙事，但未必直接转化为短期可持续交易收益。
原文全文
展开原文 · 1,762 字
CStone Pharmaceuticals, a global partner of ABL Bio (298380), confirmed a 100% complete response rate in a Phase 1b trial of CS5001 (ABL202/LCB71), an antibody-drug conjugate (ADC) drug candidate.
ABL Bio said on the 28th that CStone disclosed Phase 1b data for a CS5001 combination regimen in patients with first-line diffuse large B-cell lymphoma (DLBCL) through its semiannual business report.
CS5001 was jointly developed by combining ABL Bio's ROR1 antibody with the ADC platform technology of Ligachem Biosciences (141080). It was licensed to CStone in 2020 in a deal worth about 400 billion won ($288 million).
In the trial, 31 first-line DLBCL patients received CS5001 at doses of 40 to 90 micrograms per kilogram alongside R-CHOP, the standard treatment regimen. Complete response — meaning the cancer had entirely disappeared — was confirmed across all dose groups, for a complete response rate of 100%. The objective response rate, which also counts patients whose tumors shrank beyond a certain threshold, was likewise 100%.
CStone has decided to temporarily halt the ongoing trial and review the optimal dose and dosing interval. Because complete responses were seen even at the lowest dose of 40 micrograms per kilogram, the company plans to analyze the efficacy and safety data collected so far to identify the appropriate dose and interval for patients. It will continue development once the optimal dose and schedule are set.
"CS5001 delivered encouraging data, with a 100% complete response rate and a 100% objective response rate across all dose groups from 40 to 90 micrograms per kilogram," ABL Bio CEO Lee Sang-hoon said. "We hope it will establish itself as a new treatment option that addresses the unmet medical needs of DLBCL patients."
ABL Bio said on the 28th that CStone disclosed Phase 1b data for a CS5001 combination regimen in patients with first-line diffuse large B-cell lymphoma (DLBCL) through its semiannual business report.
CS5001 was jointly developed by combining ABL Bio's ROR1 antibody with the ADC platform technology of Ligachem Biosciences (141080). It was licensed to CStone in 2020 in a deal worth about 400 billion won ($288 million).
In the trial, 31 first-line DLBCL patients received CS5001 at doses of 40 to 90 micrograms per kilogram alongside R-CHOP, the standard treatment regimen. Complete response — meaning the cancer had entirely disappeared — was confirmed across all dose groups, for a complete response rate of 100%. The objective response rate, which also counts patients whose tumors shrank beyond a certain threshold, was likewise 100%.
CStone has decided to temporarily halt the ongoing trial and review the optimal dose and dosing interval. Because complete responses were seen even at the lowest dose of 40 micrograms per kilogram, the company plans to analyze the efficacy and safety data collected so far to identify the appropriate dose and interval for patients. It will continue development once the optimal dose and schedule are set.
"CS5001 delivered encouraging data, with a 100% complete response rate and a 100% objective response rate across all dose groups from 40 to 90 micrograms per kilogram," ABL Bio CEO Lee Sang-hoon said. "We hope it will establish itself as a new treatment option that addresses the unmet medical needs of DLBCL patients."
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。